Pulmonx (LUNG) Revenue & Revenue Breakdown
Pulmonx Revenue Highlights
Latest Revenue (Y)
$90.50M
Latest Revenue (Q)
$20.59M
Main Geography (Y)
UNITED STATES
Pulmonx Revenue by Period
Pulmonx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $90.50M | 8.01% |
| 2024-12-31 | $83.79M | 22.01% |
| 2023-12-31 | $68.67M | 27.98% |
| 2022-12-31 | $53.66M | 10.84% |
| 2021-12-31 | $48.42M | 47.91% |
| 2020-12-31 | $32.73M | 0.42% |
| 2019-12-31 | $32.59M | 62.94% |
| 2018-12-31 | $20.00M | - |
Pulmonx generated $90.50M in revenue during NA 2025, up 8.01% compared to the previous quarter, and up 276.47% compared to the same period a year ago.
Pulmonx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $20.59M | -8.90% |
| 2025-12-31 | $22.60M | 5.10% |
| 2025-09-30 | $21.50M | -9.88% |
| 2025-06-30 | $23.86M | 5.86% |
| 2025-03-31 | $22.54M | -5.16% |
| 2024-12-31 | $23.77M | 16.57% |
| 2024-09-30 | $20.39M | -1.91% |
| 2024-06-30 | $20.78M | 10.23% |
| 2024-03-31 | $18.85M | -2.20% |
| 2023-12-31 | $19.28M | 9.11% |
| 2023-09-30 | $17.67M | 2.76% |
| 2023-06-30 | $17.19M | 18.29% |
| 2023-03-31 | $14.54M | -5.77% |
| 2022-12-31 | $15.43M | 14.24% |
| 2022-09-30 | $13.50M | -3.21% |
| 2022-06-30 | $13.95M | 29.35% |
| 2022-03-31 | $10.79M | -21.32% |
| 2021-12-31 | $13.71M | 3.37% |
| 2021-09-30 | $13.26M | 8.67% |
| 2021-06-30 | $12.20M | 32.01% |
| 2021-03-31 | $9.24M | -5.96% |
| 2020-12-31 | $9.83M | -7.37% |
| 2020-09-30 | $10.61M | 188.92% |
| 2020-06-30 | $3.67M | -57.38% |
| 2020-03-31 | $8.62M | -16.71% |
| 2019-12-31 | $10.35M | 13.65% |
| 2019-09-30 | $9.10M | 23.59% |
| 2019-06-30 | $7.37M | 12.08% |
| 2019-03-31 | $6.57M | - |
Pulmonx generated $20.59M in revenue during Q1 2026, up -8.90% compared to the previous quarter, and up 86.62% compared to the same period a year ago.
Pulmonx Revenue Breakdown
Pulmonx Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| UNITED STATES | $57.02M | $56.47M | $45.92M | $32.49M | $24.99M |
| EMEA | $26.98M | $22.33M | $19.34M | $18.15M | $19.88M |
| Asia Pacific | $6.23M | $4.44M | $3.02M | $2.87M | $3.41M |
| Other International Geographical Areas | $260.00K | $556.00K | $399.00K | $155.00K | $128.00K |
Latest
Pulmonx's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (63.01%), EMEA (29.82%), Asia Pacific (6.88%), and Other International Geographical Areas (0.29%).
Quarterly Revenue by Country
| Country | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $6.57M | $7.88M | $6.63M | $7.00M | $5.48M | $6.12M | $5.13M | $5.96M | $5.12M | $4.64M | $4.85M | $5.31M | $4.53M | $5.13M | $4.41M | $4.57M | $4.05M | $5.48M | $5.61M | $4.75M |
| Other International Geographical Areas | $51.00K | $52.00K | $68.00K | $102.00K | $38.00K | $101.00K | $145.00K | $139.00K | $171.00K | $96.00K | $164.00K | $68.00K | $71.00K | $57.00K | $58.00K | $40.00K | $79.00K | $37.00K | $12.00K | - |
| Asia Pacific | $707.00K | $565.00K | $842.00K | $2.03M | $2.79M | $1.66M | $1.28M | $802.00K | $698.00K | $821.00K | $814.00K | $792.00K | $596.00K | $786.00K | $637.00K | $724.00K | $719.00K | $872.00K | $756.00K | $875.00K |
| UNITED STATES | $13.26M | $14.10M | $13.97M | $14.73M | $14.22M | $15.88M | $13.84M | $13.88M | $12.87M | $13.72M | $11.84M | $11.02M | $9.34M | $9.46M | $8.40M | $8.62M | $6.01M | $7.28M | $6.86M | $6.57M |
Latest
Pulmonx's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (64.39%), EMEA (31.93%), Asia Pacific (3.43%), and Other International Geographical Areas (0.25%).
Pulmonx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VXRT | Vaxart | $237.26M | $39.23M |
| ASRT | Assertio | $118.71M | $9.93M |
| LUNG | Pulmonx | $90.50M | $20.59M |
| TELA | TELA Bio | $80.28M | $19.06M |
| EDAP | Edap Tms | $62.42M | $17.81M |
| HYPR | Hyperfine | $13.56M | $3.90M |
| RLMD | Relmada Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| IMUX | Immunic | - | - |
| TCRX | TScan Therapeutics | - | - |